关注
Charles Baker-Glenn
Charles Baker-Glenn
Group Leader, Medicinal Chemistry, Charles River
在 crl.com 的电子邮件经过验证
标题
引用次数
引用次数
年份
Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors
AA Estrada, X Liu, C Baker-Glenn, A Beresford, DJ Burdick, M Chambers, ...
Journal of medicinal chemistry 55 (22), 9416-9433, 2012
1672012
Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors
AA Estrada, BK Chan, C Baker-Glenn, A Beresford, DJ Burdick, ...
Journal of medicinal chemistry 57 (3), 921-936, 2014
1412014
Total Synthesis of (−)‐Ulapualide A: The Danger of Overdependence on NMR Spectroscopy in Assignment of Stereochemistry
G Pattenden, NJ Ashweek, CAG Baker‐Glenn, GM Walker, JGK Yee
Angewandte Chemie International Edition 46 (23), 4359-4363, 2007
582007
Discovery of a highly selective, brain-penetrant aminopyrazole LRRK2 inhibitor
BK Chan, AA Estrada, H Chen, J Atherall, C Baker-Glenn, A Beresford, ...
ACS medicinal chemistry letters 4 (1), 85-90, 2013
532013
A catalytic asymmetric bioorganic route to enantioenriched tetrahydro-and dihydropyranones
C Baker-Glenn, N Hodnett, M Reiter, S Ropp, R Ancliff, V Gouverneur
Journal of the American Chemical Society 127 (5), 1481-1486, 2005
472005
Total synthesis of (−)-ulapualide A, a novel tris-oxazole macrolide from marine nudibranchs, based on some biosynthesis speculation
G Pattenden, NJ Ashweek, CAG Baker-Glenn, J Kempson, GM Walker, ...
Organic & Biomolecular Chemistry 6 (8), 1478-1497, 2008
412008
Alkene synthesis: elimination of arenesulfinic acid from alkyl aryl sulfones using potassium trimethylsilanolate as base
CAG Baker-Glenn, AGM Barrett, AA Gray, PA Procopiou, M Ruston
Tetrahedron letters 46 (43), 7427-7430, 2005
332005
Developing inhaled drugs for respiratory diseases: a medicinal chemistry perspective
E Pasqua, N Hamblin, C Edwards, C Baker-Glenn, C Hurley
Drug Discovery Today 27 (1), 134-150, 2022
312022
Pyrazole aminopyrimidine derivatives as LRRK2 modulators
C Baker-Glenn, DJ Burdick, M Chambers, BK Chan, H Chen, A Estrada, ...
US Patent 8,815,882, 2014
312014
Effects of ulapualide A and synthetic macrolide analogues on actin dynamics and gene regulation
E Vincent, J Saxton, C Baker-Glenn, I Moal, JD Hirst, G Pattenden, ...
Cellular and molecular life sciences 64, 487-497, 2007
222007
Aminopyrimidine derivatives as LRRK2 inhibitors
C Baker-Glenn, DJ Burdick, M Chambers, BK Chan, H Chen, A Estrada, ...
US Patent 8,354,420, 2013
212013
Mapping the structural requirements of inducers and substrates for decarboxylation of weak acid preservatives by the food spoilage mould Aspergillus niger
M Stratford, A Plumridge, MW Pleasants, M Novodvorska, ...
International Journal of Food Microbiology 157 (3), 375-383, 2012
212012
Pyrazole aminopyrimidine derivatives as LRRK2 modulators
C Baker-Glenn, DJ Burdick, BK Chan, M Chambers, H Chen, A Estrada, ...
US Patent 9,212,173, 2015
172015
Aminopyrimidine derivatives as LRRK2 modulators
C Baker-Glenn, M Chambers, BK Chan, A Estrada, D Shore, ZK Sweeney, ...
US Patent 9,145,402, 2015
172015
Aminopyrimidine derivatives as LRRK2 modulators
C Baker-Glenn, M Chambers, BK Chan, A Estrada, ZK Sweeney
US Patent 8,791,130, 2014
172014
Aminopyrimidine derivatives as LRRK2 modulators
C Baker-Glenn, DJ Burdick, M Chambers, BK Chan, H Chen, A Estrada, ...
US Patent 8,809,331, 2014
122014
Aminopyrimidine derivatives as LRRK2 modulators
C Baker-Glenn, DJ Burdick, M Chambers, BK Chan, H Chen, A Estrada, ...
US Patent 8,802,674, 2014
122014
A biocatalytic route to enantioenriched, sulfanyl aldol products
C Baker-Glenn, R Ancliff, V Gouverneur
Tetrahedron 60 (35), 7607-7619, 2004
122004
Aminopyrimidine derivatives as LRRK2 modulators
C Baker-Glenn, M Chambers, BK Chan, A Estrada, ZK Sweeney
US Patent 8,796,296, 2014
112014
Inhibitors of PDE4 enzyme and antagonists of muscarinic M3 receptor
E Armani, G Amari, M Riccaboni, C Baker-Glenn
US Patent 9,169,245, 2015
102015
系统目前无法执行此操作,请稍后再试。
文章 1–20